Altamira Therapeutics Ltd.

NASDAQ (USD): Altamira Therapeutics Ltd. (CYTO)

Last Price

1.25

Today's Change

+0.01 (0.80%)

Day's Change

1.20 - 1.28

Trading Volume

47,138

Overview

Market Cap

2 Million

Shares Outstanding

2 Million

Avg Volume

1,986,320

Avg Price (50 Days)

1.53

Avg Price (200 Days)

3.03

PE Ratio

-0.08

EPS

-16.55

Earnings Announcement

10-Jul-2024

Previous Close

1.24

Open

1.20

Day's Range

1.2 - 1.2799

Year Range

1.2 - 17.2

Trading Volume

47,138

Price Change Highlight

1 Day Change

0.81%

5 Day Change

0.00%

1 Month Change

-19.87%

3 Month Change

-25.60%

6 Month Change

-60.94%

Ytd Change

-63.87%

1 Year Change

-91.46%

3 Year Change

-99.91%

5 Year Change

-99.89%

10 Year Change

-100.00%

Max Change

-100.00%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment